We are live on ! Find out more

TRAX

First Tracks Biotherapeutics

TRAX

Market cap $1.61B

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long

First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.

First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long

See News Rankings